Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 12Recruiting 12Completed 9Not yet recruiting 8Active not recruiting 8Unknown 5Withdrawn 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1Neoplasm, Residual 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × selinexor × Clear all
NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Washington University School of Medicine

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT02628704 2023-01-26

SCORE

Karyopharm Therapeutics Inc

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT05170789 2022-05-04

ESdRRMM

Tulane University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡